Four current, individually attributable price targets form the basis of the central target. DA Davidson's Gil Luria downgraded the stock to Neutral and cut his target to $1.00 from $3.00 in August 2026. B. Riley Securities' Craig Ellis kept a Buy rating but lowered his target to $2.00 from $4.00. After the company pre-announced a third-quarter revenue shortfall in early October 2026, Rosenblatt downgraded the stock to Neutral with a $0.40 target (from $2.00), and Craig-Hallum downgraded it to Hold with a $0.35 target. The mean of these four targets is about $0.94, rounded to a central target of $0.95. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
This is not a published consensus figure; it is a calculated average of the verified targets reviewed. The wide $0.35-to-$2.00 range reflects how differently analysts weigh the company's near-term liquidity and shipment timing against its longer-term edge-AI opportunity. The cautious sub-$0.50 targets emphasize limited cash and doubts about fulfilling the NeoTensr contract, while the $2.00 target assumes execution recovers.
The shares traded near $0.44 in early October 2026, close to the 52-week low of $0.42 and far below the 52-week high of $6.76. Reaching $0.95 would require roughly a 115% advance, which is a very large move by any standard and would likely require a fundamental reset in investor expectations rather than a routine re-rating. From what I see, the path is complicated by a steep revenue decline. The company guided preliminary first-quarter 2026 revenue of about $2.7 million, then pre-announced third-quarter 2026 revenue of roughly $0.5 million and revised full-year 2026 guidance down to $32 million to $36 million, reflecting shipment timing and working-capital constraints. A move toward $0.95 would most plausibly depend on credible delivery against the NeoTensr orders and evidence that cash burn is stabilizing.
The stock sits near its 52-week low of $0.42, deep in a prolonged downtrend from the $6.76 high. The $1.00 level is a notable psychological and prior-analyst-target zone that would need to be reclaimed before the $0.95 central target could be approached with confidence. Below current levels, the $0.42 low and the $0.35-to-$0.40 analyst targets represent the nearest downside reference points. I'm watching this closely for any signs of stabilization.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms rarely publish a uniform timeline. Key items to watch include the next earnings report (estimated for November 12, 2026), fourth-quarter shipment and NeoTensr fulfillment progress, cash position and any additional financing, customer order flow, and further analyst revisions. Revenue recognition depends heavily on fourth-quarter shipments and customer payments, so any delay could materially shift the outlook.
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals help monitor volatile names such as BZAI by generating signals based on technical behavior and market conditions. This allows for more efficient tracking of shifting trends alongside traditional analysis.
The $0.95 central target is a calculated average of four verified analyst price targets spanning $0.35 to $2.00, not a guarantee or a published consensus. From a price near $0.44, it represents roughly 115% upside — a very large move that would require the company to reverse its recent revenue collapse, demonstrate credible delivery against the NeoTensr contract, and stabilize its cash position. Supportive factors include the edge-AI architecture and the up-to-$50 million NeoTensr opportunity, while the principal obstacles are guidance cuts, extreme customer concentration, dilution, and a going-concern flag. With several analysts now holding sub-$0.50 targets and one Buy-rated analyst at $2.00, investors should watch fourth-quarter shipments, cash levels, and upcoming earnings before drawing conclusions.
One thing that stands out in my own process is how Tickeron’s AI Daily Buy/Sell Signals can complement fundamental research on stocks like BZAI. By continuously scanning market data and generating actionable signals, the platform helps identify potential entry or exit points more efficiently. I have found it useful for staying on top of technical shifts in high-volatility names, especially when combined with earnings updates and contract news. This approach keeps the analysis grounded while adding a layer of data-driven perspective to the overall picture.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BZAI advanced for three days, in 72 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In 74 of 282 cases where BZAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 26%.
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BZAI as a result. In 29 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 36%.
The Moving Average Convergence Divergence Histogram (MACD) for BZAI turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 11 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 23%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BZAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
BZAI broke above its upper Bollinger Band on September 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.678) is normal, around the industry mean (51.456). P/E Ratio (0.000) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.135). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.395) is also within normal values, averaging (69.875).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. BZAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BZAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PackagedSoftware